Introduction: Giant meconium cyst resulting from antenatal bowel perforation is rare and hardly reported in multiple gestations. We found only four documented cases in the electronic literature.
Case Presentation: We report a giant meconium cyst in an 11-hour-old Nigerian boy of a discordant twin having ultrasonographic and plain radiographic diagnosis and surgical confirmation. Increasing abdominal girth from 35 cm to 41 cm within four hours of admission without ascites, pneumoperitneum and significant bowel distension make us assumed the meconium cyst to be "growing" in size. We reviewed the literature and proposed that where the fibrinous wall of meconium cyst allows for distensibility and the communication between the perforated bowel and meconium cyst persists, the meconium cyst acting as reservoir may continue to "grow" in size without remarkable intestinal distension probably, until the elastic limit is lost.
Conclusion: Meconium cyst can occur in twin pregnancy, grow to occupy the abdomen almost completely and may cause neonatal apnoea. The outcome is good post surgery.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2740019 | PMC |
| http://dx.doi.org/10.1186/1757-1626-2-7008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Outcomes of prenatal use of elexacaftor/tezacaftor/ivacaftor in carrier mothers to treat meconium ileus in fetuses with cystic fibrosis.
J Cyst Fibros
December 2024
Department of Pediatrics, University of Colorado Anschutz Medical Campus and Children's Hospital Colorado, Aurora, CO, United States.
As cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies including elexacaftor/tezacaftor/ivacaftor (ETI) have become widely used in eligible patients with cystic fibrosis (CF), the use of these medications in pregnant people has become a critical area of investigation. Since these medications appear generally safe to both mother and fetus when taken by pregnant people with CF, interest has pivoted to the use of ETI in CF carrier mothers to decrease morbidity and mortality from meconium ileus (MI) in fetuses with cystic fibrosis. Here we discuss three infants at our institution with ultrasound findings of MI who were exposed to prenatal ETI through CF carrier mothers for the purposes of treating MI and lowering risk of intestinal complications from this severe manifestation of CF.
View Article and Find Full Text PDFPolycystic ovary syndrome and gestational diabetes mellitus association to pregnancy outcomes: A national register-based cohort study.
Acta Obstet Gynecol Scand
January 2025
Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
Article Synopsis
- The study investigates the combined effects of polycystic ovary syndrome (PCOS) and gestational diabetes mellitus (GDM) on pregnancy outcomes, aiming to determine if the combination increases risks compared to having either condition alone.
- Using data from over 281,000 women who gave birth in Sweden from 1997 to 2015, the researchers analyzed various maternal and neonatal complications through logistic regression.
- The findings indicate that having GDM presents a higher risk for adverse outcomes than PCOS alone, and there was no significant interaction between the two conditions suggesting that PCOS does not increase the risk beyond GDM alone.
A Rare Case of Meckel-Gruber Syndrome with Congenital Intestinal Atresia and Abdominal Pseudocyst Clinic.
Fetal Pediatr Pathol
October 2024
Department of Pediatrics, Faculty of Medicine, Lokman Hekim University, Ankara, Turkey.
Meckel-Gruber syndrome (MGS) is a rare disease with a fatal, autosomal recessive inheritance pattern. This article mentions the neonatal MGS case followed by intestinal atresia and meconium pseudocyst clinic. Bile-containing-fluid was aspirated from the fetus, which was found to have polyhydramnios, gastric dilatation, lung hypoplasia, and cystic formation with a diameter of 68*62mm in the abdomen at 32 weeks of gestation in the intrauterine period.
View Article and Find Full Text PDFDisparities in outcomes by race and ethnicity in the Canadian cystic fibrosis population.
J Cyst Fibros
September 2024
Department of Community Health, and Epidemiology, Faculty of Medicine, Dalhousie University, Halifax, Canada. Electronic address:
Background: Cystic Fibrosis has historically been described as a disease that affects people of European ancestry. Consequently, much of what we know about CF is based on evidence generated from data collected in white individuals. This may lead to systematic bias in how non-white people with CF are diagnosed and treated.
View Article and Find Full Text PDFDirect healthcare costs in the first 2 years of life: A comparison of screened and clinically diagnosed children with cystic fibrosis - The Irish comparative outcomes study of CF (ICOS).
J Cyst Fibros
September 2024
School of Public Health, Physiotherapy and Sports Science, Unversity College Dublin, Belfield, Dublin 4, Ireland. Electronic address:
Background: In July 2011, Cystic Fibrosis (CF) was added to the Newborn Bloodspot Screening Programme in Ireland. The Irish Comparative Outcomes Study (ICOS) is a historical cohort study established to compare outcomes between clinically-detected and screen-detected children with CF. Here we present the results of economic analysis comparing direct healthcare costs in the first 2 years of life of children born between mid-2008 and mid-2016, in the pre-CF transmembrane conductance regulator modulator era.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!